| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |